iMedix Medical Content Engine 3.13.37
Home/Drugs/Tobramycin

Tobramycin: Uses, Dosage & Safety Information

Tobramycin

Tobramycin

Tobramycin

Tobramycin sulfate
Tobramycin sulfate injection is a prescription aminoglycoside antibacterial given in hospital for serious Gram-negative infections. Its boxed warning covers kidney injury, irreversible hearing and balance damage, neuromuscular blockade and fetal harm, so every patient’s kidney function and blood levels are monitored.
  • ActiveIngredient: Tobramycin sulfate
  • DosageForm: Solution for injection
  • Dosage: 10 mg/mL, 40 mg/mL
  • Indications: Serious Gram-negative infections including septicaemia, lower respiratory tract, central nervous system, intra-abdominal, skin, bone and complicated urinary tract infections
  • Manufacturer: Generic: Gland Pharma and others
  • Storage: Store as directed on the vial label
  • Drug Status: Prescription Only
Drug Status: Prescription Only
Description

What is Tobramycin?

Dosing follows the blood level
Tobramycin can cause kidney injury and irreversible hearing and balance damage. The labelling asks for kidney function and serum tobramycin concentrations to be monitored in every patient, and the dose is reduced or stopped if problems appear.1

Tobramycin sulfate injection is a prescription aminoglycoside antibacterial given intravenously or intramuscularly in hospital; vials include pharmacy bulk packages for preparing individual doses.24

It treats serious infections caused by Gram-negative bacteria such as Pseudomonas aeruginosa, E. coli and Klebsiella.

Because the gap between an effective level and a toxic one is narrow, peak and trough blood levels guide each patient’s dose.

General Instructions

How to Take Tobramycin

Given by the care team

Tobramycin is given by injection in hospital, into a vein as a diluted infusion or into a muscle; it is not a medicine taken at home without supervision.1

How much

Adults with serious infections usually receive 3 mg per kg a day in three equal doses, up to 5 mg per kg a day for life-threatening infections; children, patients with cystic fibrosis and people with high body weight are dosed differently.1

Blood levels

Blood samples are taken around doses to measure peak and trough levels; the dose is adjusted to keep them in range.1

Tell the team

Report ringing in the ears, hearing change, dizziness, numbness or muscle twitching as soon as they appear.1

What not to do

Do not start other medicines that can affect hearing or the kidneys without the care team knowing, and keep every blood-test appointment during the course.

Side Effects

What Are the Side Effects of Tobramycin?

Kidney and ear toxicity dominate the labelling; they can occur even at standard doses.1

Reactions in the Labelling
FrequencyEffectNotes
Frequency not stated in labellingRaised creatinine, reduced urine outputNephrotoxicity
Frequency not stated in labellingHearing loss, tinnitus, dizzinessCan be permanent
Frequency not stated in labellingNeuromuscular blockadeRespiratory paralysis possible
Frequency not stated in labellingLow magnesium, calcium, potassiumElectrolyte changes
Frequency not stated in labellingRash, fever, nausea, confusionLess serious reactions

Source: 1

Seek immediate medical attention if:
  • Sudden hearing loss or severe dizziness
  • Weakness or difficulty breathing
  • Passing very little urine
Uses

What is Tobramycin Used For?

Labelled Indications
IndicationNotes
Septicemia in children and adultsP. aeruginosa, E. coli, Klebsiella
Lower respiratory tract infectionsSusceptible organisms
Serious central nervous system infectionsIncluding meningitis
Intra-abdominal, skin, bone and complicated urinary infectionsSusceptible organisms

Source: 1

Tobramycin injection is used only for serious infections proven or strongly suspected to be caused by susceptible bacteria.1

Safety Advice

Interactions Alcohol:

Consult your doctor
The label sets no alcohol restriction. This is a hospital injection given for serious infection, so the practical question rarely arises during treatment.

Interactions Other Medications:

Unsafe
Potent diuretics such as furosemide enhance ototoxicity. Cephalosporins, amphotericin B, cisplatin and vancomycin add to kidney injury. Anaesthetics and neuromuscular blocking agents can precipitate respiratory paralysis. Almost every significant interaction adds to the same two toxicities.

Special Groups Pregnancy:

Unsafe
Aminoglycosides cross the placenta, and eighth-nerve damage has been reported in infants after maternal exposure to this class. Use in pregnancy is weighed against that specific documented risk.

Special Groups Breastfeeding:

Consult your doctor
The prescribing information does not establish a breastfeeding recommendation. Oral absorption of aminoglycosides is poor, which is relevant to the infant, but the decision belongs to the treating team.

Special Groups Elderly:

Use with caution
Renal function declines with age, and tobramycin is cleared by the kidney. Reduced clearance raises concentrations, and concentration is what drives both toxicities. Dose and interval are adjusted accordingly.

Special Groups Children:

Use with caution
Dosing is established for neonates and children at 6 to 7.5 mg/kg per day in divided doses. Monitoring matters as much as the number: hearing loss in a child who cannot report early tinnitus is the specific concern.

Effects on Activities Driving:

Consult your doctor
Vestibular toxicity produces vertigo and unsteadiness that can persist after treatment. Anyone who has noticed dizziness or imbalance during a course should discuss driving before resuming it.

Effects on Activities Operating Machinery:

Consult your doctor
The same balance disturbance applies, and hearing loss adds a second problem where audible alarms matter.
Regulatory status and dispensing

Tobramycin injection is prescription-only and used in hospital settings.4

Warnings

Critical Warnings for Tobramycin Use

Boxed warning
Tobramycin can cause nephrotoxicity, irreversible ototoxicity, neuromuscular blockade and fetal harm; kidney function and serum levels are monitored in all patients.1

Aminoglycoside hypersensitivity

Contraindicated: History of hypersensitivity to tobramycin or any other aminoglycoside.1

Nephrotoxicity

Acute kidney injury can occur; kidney function and serum levels are monitored, and the dose is reduced or stopped if it develops.1

Ototoxicity

Irreversible auditory and vestibular toxicity can occur; treatment stops if it develops.1

Fetal harm

Aminoglycosides can cause fetal harm, including congenital deafness.1

See Interactions.

Dosage

Dosage

Tobramycin Products
FormulationActive IngredientsClinical Note
Injection (vials; pharmacy bulk package 1.2 g)Tobramycin sulfateIntravenous or intramuscular
Renal impairmentTobramycinDose reduced or interval extended, guided by levels
Hepatic impairmentTobramycinNo specific adjustment stated
Cystic fibrosisTobramycinHigher doses guided by levels

Source: 14

Exceeding the dose
Overdose worsens the known toxicities, including kidney damage, ototoxicity and neuromuscular blockade; haemodialysis removes tobramycin.1
Interactions

What Does Tobramycin Interact With?

Every row adds to the toxicities in the boxed warning.

Interactions by Severity
Interacting SubstanceEffect and RiskSeverityDocumentation
Other aminoglycosides and other drugs toxic to the kidneys or earsAdditive kidney and ear toxicityMajorGood — labelled interaction
Anaesthetics and neuromuscular blocking agentsNeuromuscular blockadeMajorGood — labelled interaction

Source: 1

FAQs
Peak and trough levels show whether the dose is effective without reaching levels that damage the kidneys or ears.
Yes. Hearing and balance damage can be irreversible; report ringing in the ears or dizziness promptly.
No. The drops and inhaled forms are separate products with much lower body exposure.
People allergic to tobramycin or any other aminoglycoside.
Aminoglycosides can harm the unborn baby, including causing deafness; the team weighs this carefully.
Evidence and Reported Data

Evidence Scope

Established: tobramycin injection is nephrotoxic and ototoxic, and serum-level monitoring guides dosing. Unknown: individual susceptibility, which is why every patient is monitored.1

What has been reported to the FDA

As of the FAERS data cut of 30 July 2026, the FDA Adverse Event Reporting System held 15,615 reports naming tobramycin, of which 11,986 were classed as serious — 77% of the total.3

Most Reported Terms
Coded termReports
Off label use982
Pneumonia952
Drug ineffective829
Dyspnoea794
Acute kidney injury746
How to read this table

FAERS records what was reported, not what the medicine caused, and has no denominator – no count can become a rate.

Figures above are the counts held at the 30 July 2026 data cut, retrieved on 2 September 2026; they do not update between cuts.

Population note: these reports cover all tobramycin products, and the inhaled formulation used long-term in cystic fibrosis contributes heavily. That explains pneumonia and dyspnoea near the top — they are features of the underlying lung disease as much as of the drug. Acute kidney injury in fifth place is the term that maps onto the injection described here. Reports name the product, not the formulation, and not the culprit.

Who was this medicine studied in?

Tobramycin injection was approved in 1975, before the Drug Trials Snapshots programme.5

Where to report and verify

Routing to Official Registries
What you needWhere to go
Report a side effectFDA MedWatch
Pregnancy-specific dataMotherToBaby
Full prescribing informationDailyMed
Verify a pharmacy websiteFDA BeSafeRx · LegitScript
References

References

  1. FDA Prescribing Information, Tobramycin for Injection USP, pharmacy bulk package (Fresenius Kabi, NDA 050789) — Boxed Warning, Indications and Usage, Dosage and Administration 2.1–2.8, Contraindications, Warnings and Precautions 5.1–5.4, Adverse Reactions, Overdosage, How Supplied
    Label effective 2024-02-07 · Accessed 2026-09-28
    Used for: boxed toxicities, dosing and monitoring, interactions, overdose.
    dailymed.nlm.nih.gov — DailyMed
  2. Drugs@FDA — tobramycin injection applications
    Records · Accessed 2026-09-28
    Used for: marketing status.
    accessdata.fda.gov — Drugs@FDA
  3. openFDA — FDA Adverse Event Reporting System, drug event query for tobramycin
    Data cut 2026-07-30 · Accessed 2026-09-28
    Used for: report totals, serious counts and most reported terms.
    open.fda.gov — openFDA
  4. FDA Orange Book — tobramycin sulfate injection
    Current edition · Accessed 2026-09-28
    Used for: reference-standard and generic availability.
    accessdata.fda.gov — Orange Book
  5. FDA — Drug Trials Snapshots programme scope
    Programme current · Accessed 2026-09-28
    Used for: confirmation that Snapshots cover novel drugs approved from 2015.
    fda.gov — Drug Trials Snapshots

Review cycle. Clinical review completed 28 September 2026. Next review due by 28 September 2027, or earlier if the labelling is revised.

Disclaimer

Disclaimer: The information on this site is provided for informational purposes only and is not medical advice. It does not replace professional medical consultation, diagnosis, or treatment. Do not self-medicate based on the information presented on this site. Always consult with a doctor or other qualified healthcare professional before making any decisions about your health.